Hantz Financial Services’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.58M Sell
58,496
-3,189
-5% -$217K 0.06% 201
2026
Q1
$3.99M Sell
61,685
-16,228
-21% -$1.14M 0.06% 216
2025
Q4
$5.24M Sell
77,913
-20,021
-20% -$1.35M 0.08% 188
2025
Q3
$7.18M Sell
97,934
-36,846
-27% -$2.45M 0.11% 167
2025
Q2
$7.01M Sell
134,780
-17,004
-11% -$968K 0.11% 174
2025
Q1
$9.69M Buy
151,784
+12,874
+9% +$748K 0.17% 119
2024
Q4
$6.64M Sell
138,910
-22,862
-14% -$1.17M 0.12% 181
2024
Q3
$9.26M Buy
+161,772
New +$9.27M 0.16% 149

Other funds holding HALO

Hantz Financial Services's HALO Position: Q2 2026 in Review

Hantz Financial Services reduced its Halozyme (HALO) stake by 5.2% in Q2 2026, selling an estimated $217K and leaving 58,496 shares worth $4.58M. The position accounts for 0.06% of the portfolio, ranked #201.

Hantz Financial Services first reported a position in HALO in Q3 2024 and has held it in 8 quarters since. The position peaked at $9.69M in Q1 2025. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Hantz Financial Services held 58,496 shares of Halozyme worth $4.58M as of Q2 2026.
  • Hantz Financial Services sold 3,189 Halozyme shares in Q2 2026, an estimated $217K.
  • Halozyme made up 0.06% of Hantz Financial Services's portfolio in Q2 2026, its #201 holding.
  • Hantz Financial Services first reported a position in Halozyme in Q3 2024 and has held it in 8 quarters since.
  • Hantz Financial Services's Halozyme position peaked at $9.69M in Q1 2025.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.